1071001-11-0

Basic information

• Product Name: 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-one
• Synonyms: 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-one
• CAS NO: 1071001-11-0
• Molecular Weight: 330.245
• Mol File: 1071001-11-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-one(1071001-11-0)
• EPA Substance Registry System: 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-one(1071001-11-0)

Safety Data

• Hazardous Substances Data: 1071001-11-0(Hazardous Substances Data)

Upstream product

• 754-34-7 1,1,1,2,2,3,3-heptafluoro-3-iodo-propane 
• 336-59-4 heptafluorobutyric anhydride 
• 20371-41-9 5-phenylvaleric acid chloride 
• 1071001-86-9 1-(morpholin-4-yl)-5-phenylpentan-1-one 
• 1073633-01-8 1,1,1,2,2,3,3-heptafluoro-8-phenyl-octan-4-ol 
• 118514-42-4 5-phenyl-pentanoic anhydride 
• 2270-20-4 5-Phenylpentanoic acid 

Relevant articles and documents

Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as a novel pharmaceutical target. We have now explored the Structure-activity relationship between fluoroketones and GVIA iPLA2 inhibition. The presence of a naphthyl group proved to be of paramount importance. 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one (FKGK18) is the most potent inhibitor of GVIA iPLA2 (XI(50) = 0.0002) ever reported. Being 195 and >455 times more potent for GVIA iPLA 2 than for GIVA cPLA2 and GV sPLA2, respectively, makes it a valuable tool to explore the role of GVIA iPLA 2 in cells and in vivo models. 1,1,1,2,2,3,3-Heptafluoro-8- (naphthalene-2-yl)octan-4-one inhibited GVIA iPLA2 with a X I(50) value of 0.001 while inhibiting the other intracellular GIVA cPLA2 and GV sPLA2 at least 90 times less potently. Hexa- and octafluoro ketones were also found to be potent inhibitors of GVIA iPLA 2; however, they are not selective.

PERFLUOROKETONE COMPOUNDS AND USES THEREOF

Novel perfluoroketone compounds of formula [I] and [Ia] are described Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and / or inflammatory conditions, such as demeyelmatmg (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury).